Ralph Schiess
Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies
Steuber T, Tennstedt P, Macagno A, Athanasiou A, Wittig A, Huber R, Golding B, Schiess R, Gillessen Sommer S. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies. BJU Int 2018
14.09.2018Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies
14.09.2018BJU Int 2018
Steuber Thomas, Tennstedt Pierre, Macagno Annalisa, Athanasiou Alcibiade, Wittig Anja, Huber Ramy, Golding Bruno, Schiess Ralph, Gillessen Sommer Silke
Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
Sajic T, Claassen M, Gillessen Sommer S, Omlin A, Malander S, Niméus E, Friedrich B, Blattmann P, Chen R, Brentnall T, Pan S, Sethi A, Hüttenhain R, Schiess R, Williams E, Surinova S, Arvaniti E, Liu Y, Aebersold R. Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. Cell Rep 2018; 23:2819-2831.e5.
29.05.2018Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
29.05.2018Cell Rep 2018; 23:2819-2831.e5
Sajic Tatjana, Claassen Manfred, Gillessen Sommer Silke, Omlin Aurelius, Malander Susanne, Niméus Emma, Friedrich Betty, Blattmann Peter, Chen Ru, Brentnall Teresa A, Pan Sheng, Sethi Atul, Hüttenhain Ruth, Schiess Ralph, Williams Evan G, Surinova Silvia, Arvaniti Eirini, Liu Yansheng, Aebersold Ruedi
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer
Endt K, Joos T, Gillessen Sommer S, Steuber T, Engeler D, Rainisio M, Guenther A, Tennstedt P, Athanasiou A, Omlin A, Goepfert J, Schiess R. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PloS one 2017; 12:e0181557.
02.08.2017Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer
02.08.2017PloS one 2017; 12:e0181557
Endt Kathrin, Joos Thomas, Gillessen Sommer Silke, Steuber Thomas, Engeler Daniel, Rainisio Maurizio, Guenther Anna, Tennstedt Pierre, Athanasiou Alcibiade, Omlin Aurelius, Goepfert Jens, Schiess Ralph
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)
Rothermundt C, Cathomas R, Rüschoff J, Schiess R, Endt K, Lui L, Pollak M, Bärtschi D, Strebel R, Winterhalder R, Templeton A, Hayoz S, Gillessen Sommer S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol 2014; 66:468-74.
04.01.2014Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)
04.01.2014Eur Urol 2014; 66:468-74
Rothermundt Christian, Cathomas Richard, Rüschoff Jan H, Schiess Ralph, Endt Kathrin, Lui Lillianne, Pollak Michael, Bärtschi Daniela, Strebel Räto T, Winterhalder Ralph, Templeton Arnoud, Hayoz Stefanie, Gillessen Sommer Silke
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.
06.04.2013Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
06.04.2013Eur Urol 2013; 64:150-8
Templeton Arnoud, Schiess Ralph, Wild Peter J, Rüschoff Jan H, Thalmann George, Dietrich Pierre-Yves, Aebersold Ruedi, Klingbiel Dirk, Gillessen Sommer Silke, Müller Beat, Winterhalder Ralph, Stenner Frank, Dutoit Valérie, Cathomas Richard, Rothermundt Christian, Bärtschi Daniela, Dröge Cornelia, Gautschi Oliver, Borner Markus, Fechter Eva, Swiss Group for Clinical Cancer Research (SAKK)
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
12.09.2012Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
12.09.2012Clin Cancer Res 2012; 18:6049-57
Cathomas Richard, Gillessen Sommer Silke, von Moos Roger, Schiess Ralph, Pless Miklos, Berthold Dominik R, Siciliano Daniele, Winterhalder Ralph, Droege Cornelia, Cotting Denise, Brauchli Peter, Betticher Daniel C, Jaggi Rolf, Bubendorf Lukas, Klingbiel Dirk, Rothermundt Christian, Swiss Group for Clinical Cancer Research SAKK
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome
Kaelin M, Krek W, Aebersold R, Cerny T, Templeton A, Wild P, Powles T, Fankhauser N, Schiess R, Cima I, Gillessen Sommer S. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. Eur Urol 2011; 60:1235-43.
29.06.2011Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome
29.06.2011Eur Urol 2011; 60:1235-43
Kaelin Martin, Krek Wilhelm, Aebersold Ruedi, Cerny Thomas, Templeton Arnoud, Wild Peter, Powles Tom, Fankhauser Niklaus, Schiess Ralph, Cima Igor, Gillessen Sommer Silke
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
Cima I, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, Aebersold R, Leippold T, Fuchs T, Schubert O, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci USA 2011; 108:3342-7.
07.02.2011Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
07.02.2011Proc Natl Acad Sci USA 2011; 108:3342-7
Cima Igor, Wyler Stephen, Zehetner Jens, Jochum Wolfram, Buhmann Joachim, Cerny Thomas, Moch Holger, Gillessen Sommer Silke, Aebersold Ruedi, Leippold Thomas, Fuchs Thomas, Schubert Olga, Schiess Ralph, Wild Peter, Kaelin Martin, Schüffler Peter, Lange Vinzenz, Picotti Paola, Ossola Reto, Templeton Arnoud, Krek Wilhelm